Abstract: Objective The aim of this study was to summarize clinical feature and outcomes of 80 patients with drug-induced liver injury (DILI). Methods The clinical data of 80 patients with DILI were retrospectively analyzed in our hospital between January 2021 and December 2023, the alleged medicines were discontinued and liver-protecting agents were given for one to three weeks. The outcomes was recorded. Results As for clinical catalogue in 80 patients with DILI, hepatocellular type was found in 41 cases (51.3%), cholestatic type in 14 cases (17.5%) and mixed type in 25 cases (31.2%); gastrointestinal symptoms was found in 51.2% of patients with hepatocellular type, much higher than 21.4% of patients with cholestatic type or 24.0% of those with mixed type; serum ALT level in patients with hepatocellular type was (646.2±177.5) U/L, much higher than [(91.4±28.9)U/L, P<0.05] in with cholestatic type or [(140.8±42.4)U/L, P<0.05] in with mixed type, AST level was 430.7±123.9)U/L, much higher than [(111.4±42.6)U/L, P<0.05] in cholestatic type or [(129.1±60.7)U/L, P<0.05] in mixed type, ALP level was (90.6±19.4)U/L, much lower than [(258.1±83.3)U/L, P<0.05] in with cholestatic type or [(191.4±50.8)U/L, P<0.05] in mixed type, and GGT level was (263.9±100.7)U/L, much lower than [(881.4±350.2)U/L, P<0.05] in with cholestatic type or [(475.1±192.3)U/L, P<0.05] in mixed type; 69 patients (86.3%) in our series recovered and 11 patients (13.7%) didn’t, without significant differences among patients with different clinical catalogue (P>0.05). Conclusion The most common clinicaltype of patients with DILI is hepatocellular, with digestive symptoms more common. Most DILI patients have good prognosis, while liver injury caused by herbal medicines cannot be ignored.

Key words: Drug-induced liver injury, Clinical feature, Prognosis